17 alpha-Hydroxyprogesterone Caproate (Delalutin)

Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS.

Also Known As:

Delalutin; 17 alpha-Oxyprogesterone Capronate; 17-Hydroxyprogesterone Capronate; 17-alpha-Hydroxy-Progesterone Caproate; Hydroxyprogesterone Caproate; Hydroxyprogesterone Hexanoate; Makena; Neolutin; Oxyprogesterone Caproate; Prolutin Depot; Proluton Depot; 17 Hydroxyprogesterone Capronate; 17 alpha Hydroxy Progesterone Caproate; 17 alpha Hydroxyprogesterone Caproate; 17 alpha Oxyprogesterone Capronate; Caproate, 17-alpha-Hydroxy-Progesterone; Hexanoic acid, 3,20-dioxopregn-4-en-17-yl ester

Networked: 173 relevant articles (11 outcomes, 43 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Iams, Jay D: 13 articles (12/2021 - 09/2005)
2.	Caritis, Steve N: 13 articles (01/2018 - 09/2005)
3.	Rouse, Dwight J: 11 articles (10/2021 - 08/2007)
4.	Varner, Michael W: 11 articles (01/2018 - 09/2005)
5.	Mercer, Brian M: 11 articles (12/2017 - 08/2007)
6.	Spong, Catherine Y: 9 articles (07/2013 - 09/2005)
7.	Peaceman, Alan M: 8 articles (01/2017 - 09/2005)
8.	Sorokin, Yoram: 8 articles (01/2017 - 08/2007)
9.	Manuck, Tracy A: 7 articles (01/2018 - 08/2011)
10.	Ramin, Susan M: 7 articles (01/2017 - 09/2005)

Related Diseases

1.	Premature Birth (Birth, Premature) 06/19/2007 - "Prophylactic administration of 17-alpha hydroxyprogesterone caproate (17OHPC) has proven to be effective in the prevention of preterm birth in women with singleton pregnancies with a previous preterm delivery. " 10/01/2011 - "Intramuscular 17 α-hydroxyprogesterone caproate (identical in formulation and manufacturing process to Makena™, thus hereafter referred to as Makena™) 250 mg once weekly, initiated at 16-20 weeks' gestation, was effective in reducing the risk of preterm birth in women with a singleton pregnancy at high risk of delivering preterm in a large, well designed, placebo-controlled trial (n = 463 randomized). " 10/01/2023 - "We report that disparate findings and conclusions between similarly designed rigorous studies may reflect differences in a priori risk and population incidence and extreme care should be taken in interpreting the studies and making decisions regarding efficacy of 17-alpha hydroxyprogesterone caproate for the prevention of preterm birth. " 01/01/2021 - "This clinical opinion is a critical appraisal of the 2 randomized trials examining the efficacy of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth and a chronicle of events in the regulatory process of drug approval to help answer this question. " 11/01/2021 - "To perform a systematic review and meta-analysis of all randomized controlled trials (RCTs) that investigated the clinical benefits of 17-alpha hydroxyprogesterone caproate (17OHPC) in the prevention of recurrent preterm birth (PTB) among singleton pregnant women with a previous history of PTB. "
2.	Endometrial Neoplasms (Endometrial Cancer) 08/01/1995 - "Thirty-nine patients of endometrial cancer were treated with hydroxyprogesterone caproate, AG or combination of both, and their effects were compared. " 01/01/1985 - "Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. " 12/01/1982 - "Adjuvant hydroxyprogesterone caproate in stage I endometrial carcinoma: changes in numbers and reactivities of some blood lymphocyte subpopulations." 01/01/1976 - "[Use of 19-nor-17 alpha-hydroxyprogesterone caproate in endometrial cancer]." 08/01/1974 - "The treatment of advanced endometrial cancer with hydroxyprogesterone caproate."
3.	Adenocarcinoma 01/15/1980 - "A prospective trial was initiated in 1972 utilizing Depo-Provera in women with metastatic or recurrent endometrial adenocarcinoma to evaluate if the objective response and survival would be significantly improved in comparison to patients previously treated with Delalutin at a similar dose. " 05/01/1971 - "Postmenopausal women with recurrent or metastatic adenocarcinoma of the endometrium were treated with Delalutin (17-alpha-hydroxyprogesterone caproate), Depo-Provera (6-methyl-17-alpha-hydroxyprogesterone acetate), or Colprone (6,17-dimethyl-6-dehydroprogesterone). " 01/15/1980 - "Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma."
4.	Uterine Anomalies 04/01/2015 - "The objective of the study was to evaluate the efficacy of 17 alpha-hydroxyprogesterone caproate (17OHP-C) in prolonging gestation in patients with a short cervix and other risk factors for preterm delivery, such as previous preterm birth, cervical surgery, uterine anomalies, or prenatal diethylstilbestrol (DES) exposure. "
5.	Breast Neoplasms (Breast Cancer) 10/01/1961 - "Objective remission of metastatic breast carcinoma in a male who recieved 17-alpha hydroxy progesterone caproate (delalutin)."

Related Drugs and Biologics

1.	Progesterone
2.	17 alpha-Hydroxyprogesterone Caproate (Delalutin)
3.	Progestins (Progestagens)
4.	Medroxyprogesterone Acetate (Depo-Provera)
5.	hexanoic acid (hexanoate)
6.	Diethylstilbestrol (Stilbestrol)
7.	Suppositories (Vaginal Suppositories)
8.	Hormones (Hormone)
9.	Tamoxifen
10.	Estrogens (Estrogen)

Related Therapies and Procedures

1.	Radiotherapy
2.	Therapeutics
3.	Tocolysis
4.	Injections
5.	Pessaries